Antiproliferative Effect of Androgen Receptor Inhibition in Mesenchymal Stem-Like Triple-Negative Breast Cancer | Zendy

Aiyu Zhu | Zendy; Yan Li | Zendy; Wei Song | Zendy; Yumei Xu | Zendy; Fang Yang | Zendy; Wenwen Zhang | Zendy; Yongmei Yin | Zendy; Xiaoxiang Guan | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Antiproliferative Effect of Androgen Receptor Inhibition in Mesenchymal Stem-Like Triple-Negative Breast Cancer

Author(s) -

Aiyu Zhu,

Yan Li,

Wei Song,

Yumei Xu,

Fang Yang,

Wenwen Zhang,

Yongmei Yin,

Xiaoxiang Guan

Publication year - 2016

Publication title -

cellular physiology and biochemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.486

H-Index - 87

eISSN - 1421-9778

pISSN - 1015-8987

DOI - 10.1159/000443052

Subject(s) - bicalutamide , androgen receptor , triple negative breast cancer , cancer research , cyclin d1 , dihydrotestosterone , biology , cell growth , viability assay , chemistry , breast cancer , apoptosis , medicine , cancer , endocrinology , cell cycle , androgen , prostate cancer , hormone , biochemistry , genetics

Androgen receptor (AR), a steroid hormone receptor, has recently emerged as prognostic and treatment-predictive marker in breast cancer. Previous studies have shown that AR is widely expressed in up to one-third of triple-negative breast cancer (TNBC). However, the role of AR in TNBC is still not fully understood, especially in mesenchymal stem-like (MSL) TNBC cells.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research